Skip to content

Heart Disease Health Center

Shorter Plavix Treatment May Be Equally Effective

Study Shows 6 Months of Blood Thinner After Stent Placement May Be Safer, as Effective as 2-Year Treatment
Font Size
A
A
A
By
WebMD Health News
Reviewed by Laura J. Martin, MD

Aug. 30, 2011 (Paris) -- Taking the blood thinner Plavix for six months after receiving a stent may be safer and just as effective as two years of treatment, a new study suggests.

The standard recommendation is typically at least 12 months of Plavix. But the study found that six months of treatment was enough to prevent rare but deadly complications, says researcher Marco Valgimigli, MD, of the University Hospital of Ferrara, in Italy.

Stents are tiny mesh tubes used to prop open an artery after a balloon angioplasty procedure opens the clogged artery.

As blood flows through the stent, clots can develop. The clots can lodge in an artery, causing a heart attack.

That's why people who get stents get blood-thinning treatment with a combination of aspirin and Plavix or similar drugs.

But no one really knows how long patients should stay on Plavix. Current guidelines call for at least one year of treatment, but "there's still a high degree of uncertainty," Valgimigli tells WebMD.

Shorter Plavix Treatment Safer, Just as Effective

The new study, dubbed PRODIGY, involved nearly 2,000 patients who received either a bare-metal stent or a newer drug-coated stent. They were divided into two groups: One got Plavix and aspirin for six months, and the other for two years.

The results were presented here at the European Society of Cardiology Congress 2011.

About 10% of people in both groups had a heart attack or stroke or died, showing "six months may be enough," Valgimigli says.

The reason for the shorter duration of Plavix use comes down to the finding that patients getting two years of treatment were about twice as likely to have a serious bleed: 7.4% vs. 3.5% of those on six months of therapy.

Further analysis showed that the results held true regardless of age, sex, type of stent, and severity of disease. However, "we will dig further into these subgroups," Valgimigli says.

One study isn't enough to change guidelines. But two other recent studies have shown similar results, according to Valgimigli.

American Heart Association President Gordon Tomaselli, MD, director of cardiology at Johns Hopkins Medical Institutions, tells WebMD that the studies are likely to prompt the organization to revisit guidelines on the optimal duration of Plavix treatment for patients with stents.

Today on WebMD

x-ray of human heart
A visual guide.
atrial fibrillation
Symptoms and causes.
 
heart rate graph
10 things to never do.
heart rate
Get the facts.
 
empty football helmet
Article
red wine
Video
 
eating blueberries
Article
Simple Steps to Lower Cholesterol
Slideshow
 
Inside A Heart Attack
SLIDESHOW
Omega 3 Sources
SLIDESHOW
 
Salt Shockers
SLIDESHOW
lowering blood pressure
SLIDESHOW